Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

F6127

Sigma-Aldrich

Fludrocortisone acetate

≥98%

Synonym(s):

9α-Fluoro-11β,17α,21-trihydroxy-4-pregnene-3,20-dione acetate, 9-Fluorocortisol acetate, 9-Fluorohydrocortisone acetate

Sign Into View Organizational & Contract Pricing

Select a Size

1 G
$98.00
5 G
$351.90

$98.00

Available to ship onMay 08, 2025Details

Request a Bulk Order
Notify Me

Get notified when this item is ready to ship via email.

All Photos(1)

Select a Size

Change View
1 G
$98.00
5 G
$351.90

About This Item

Empirical Formula (Hill Notation):
C23H31FO6
CAS Number:
514-36-3
Molecular Weight:
422.49
EC Number:
208-180-4
MDL number:
MFCD00864160
UNSPSC Code:
12352200
PubChem Substance ID:
24894899
NACRES:
NA.77

$98.00

Available to ship onMay 08, 2025Details

Request a Bulk Order
Notify Me

Get notified when this item is ready to ship via email.

biological source

synthetic

sterility

non-sterile

assay

≥98%

form

powder

solubility

acetone: 50 mg/mL, clear, colorless to light yellow

shipped in

ambient

storage temp.

room temp

SMILES string

CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C

InChI

1S/C23H31FO6/c1-13(25)30-12-19(28)22(29)9-7-16-17-5-4-14-10-15(26)6-8-20(14,2)23(17,24)18(27)11-21(16,22)3/h10,16-18,27,29H,4-9,11-12H2,1-3H3/t16-,17-,18-,20-,21-,22-,23-/m0/s1

InChI key

SYWHXTATXSMDSB-GSLJADNHSA-N

Gene Information

human ... NR3C2(4306)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Fludrocortisone acetate is secreted by adrenal cortex. It increases the reabsorption of sodium and secretion of potassium and hydrogen.[1] Fludrocortisone is used to treat cerebral salt wasting syndrome[2] and adrenal insufficiency.[3] Fludrocortisone improves the sensitivity of blood vessels to catecholamines and increases the blood volume.[4]

Biochem/physiol Actions

Fludrocortisone acetate is a synthetic corticosteroid with more mineralocorticoid than glucocorticoid activity.

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Warning

hcodes

H302,H361

Hazard Classifications

Acute Tox. 4 Oral - Repr. 2

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCG3165
BCBV4395
BCBR1170V
BCBR1170
BCBQ4707V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Dong-Min Kim et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 22(11), 3273-3276 (2007-07-10)
Hyperkalaemia is a commonly encountered problem in dialysis patients with end-stage renal disease (ESRD). The aim of the present study was to assess the effect of fludrocortisone acetate (FCA) on reducing serum potassium levels in haemodialysis (HD) patients with hyperkalaemia.
R Taniguchi et al.
The Tohoku journal of experimental medicine, 186(3), 215-223 (1999-05-29)
It is known that some patients with primary aldosteronism show postoperative hyperkalemia, which is due to inability of the adrenal gland to secrete sufficient amounts of aldosterone. However, hyperkalemia is generally neither severe nor prolonged, in which replacement therapy with
S Yamashiro et al.
Acta neurochirurgica, 139(10), 987-990 (1997-01-01)
This 67 year-old man experienced 3 episodes of symptomatic hyponatraemia. Radiological examination revealed a sellar lesion and the tumour was removed via the transsphenoidal route. Thereafter, he simultaneously developed intractable diabetes insipidus and serious hyponatraemia with persistent natriuresis. His level
Clinical Pharmacology Made Incredibly Easy! (2009)
Cecilia Mattsson et al.
Nature clinical practice. Nephrology, 2(4), 198-208 (2006-08-26)
Primary aldosteronism is caused by bilateral idiopathic hyperplasia in approximately two-thirds of cases and aldosterone-producing adenoma in one-third. Most patients with primary aldosteronism are normokalemic. In the clinical setting of normokalemic hypertension, patients who have resistant hypertension and hypertensive patients
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service